BRIEF published on 11/06/2024 at 13:47, 15 days ago Medincell: 2024 revenues on the rise and significant clinical progress Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 15 days ago Inside Information / Other news releases Medincell achieves 25% increase in 2024 UZEDY® revenue outlook reaching $100M and key milestone in Olanzapine LAI Phase 3 clinical trials. Teva Pharmaceuticals shares Q3 results Revenue Clinical Trials Medincell Teva Pharmaceuticals UZEDY
BRIEF published on 10/01/2024 at 15:47, 1 month 19 days ago Threshold crossing by Mirova in MEDINCELL Capital Actions Threshold Crossing Medincell Mirova
BRIEF published on 09/24/2024 at 11:54, 1 month 27 days ago Teva and Medincell Present Promising Results on Olanzapine LAI for Schizophrenia Clinical Trial Schizophrenia Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/24/2024 at 11:53, 1 month 27 days ago Inside Information / Other news releases Teva and Medincell reveal positive efficacy, safety, and tolerability data from Phase 3 study on Olanzapine LAI for schizophrenia treatment, presenting at ECNP 2024 Schizophrenia Treatment Phase 3 Study Medincell Teva Olanzapine LAI
BRIEF published on 09/18/2024 at 10:13, 2 months 3 days ago Mirova crosses the threshold of 5% of voting rights in MEDINCELL Voting Rights Actions Threshold Crossing Medincell Mirova
BRIEF published on 09/11/2024 at 07:35, 2 months 10 days ago Medincell establishes a new liquidity contract with Rothschild Martin Maurel Common Shares Euronext Paris Liquidity Contract Rothschild Martin Maurel Medincell
PRESS RELEASE published on 09/11/2024 at 07:30, 2 months 10 days ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract Medincell appoints ROTHSCHILD MARTIN MAUREL for liquidity contract management on Euronext Paris, complying with AMF Decision 2021-01 Euronext Paris Liquidity Contract Rothschild Martin Maurel AMF Decision Medincell
BRIEF published on 09/05/2024 at 07:35, 2 months 16 days ago Medincell: Promising advances for injectable Olanzapine Schizophrenia Phase 3 Medincell Olanzapine Teva Pharmaceuticals
PRESS RELEASE published on 09/05/2024 at 07:30, 2 months 16 days ago Inside Information / Other news releases Teva provides update on pivotal Phase 3 of Olanzapine LAI by Medincell. Safety results on track for H2 2024. Potential innovative long-acting antipsychotic treatment Clinical Trials Phase 3 Medincell Teva Olanzapine LAI
Published on 11/21/2024 at 13:30, 35 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 35 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 1 hour 5 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 1 hour 5 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 1 hour 5 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 29 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 50 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 7 hours 7 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 45 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 20 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 20 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
